Alembic Pharmaceuticals announces its first injectable product approval from its General Sterile Facility – Final Approval for Glycopyrrolate Injection USP Kumar Jeetendra | November 1, 2022 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Glycopyrrolate Injection USP, 0.2 mg/1 mL and 0.4 mg/2 mL (0.2 mg/mL) Single-dose Vials and 1 mg/5 mL (0.2 mg/mL) and 4 mg/20 mL (0.2 mg/mL) Multiple-dose Vials. …
Alembic Pharmaceuticals receives USFDA Final Approval for Paclitaxel Injection USP Kumar Jeetendra | October 27, 2022 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Paclitaxel Injection USP, 30 mg/5 mL (6 mg/mL), 100 mg/16.7 mL (6 mg/mL), and 300 mg/50 mL (6 mg/mL) Multiple-Dose Vials. This is the first product approval …
Aragen to operationalize cutting-edge formulation manufacturing facility Kumar Jeetendra | October 21, 2022 Aragen, a leading Contract Research Development and Manufacturing Organization (CRDMO), today announced that it will operationalize its state-of-the-art formulation manufacturing facility in the Mallapur campus, Hyderabad, India by January 2023. The 12,000 square feet new facility will strengthen the company’s ability to deliver clinical supplies to customers through its integrated drug substance and drug product …
Parexel Recognized by Frost & Sullivan with 2022 Global Customer Value Leadership Award Kumar Jeetendra | October 19, 2022 Based on its recent analysis of the global decentralized clinical trials (DCT) industry, Frost & Sullivan has recognized leading global clinical research organization (CRO) Parexel with the 2022 Global Customer Value Leadership Award. Parexel combines in-house expertise, patient and caregiver insights, and cutting-edge technologies to plan, operationalize, and deliver DCTs for biopharmaceutical customers worldwide while …
VINCOV-19, an antidote, and a cure against COVID-19, successfully completes Phase 2 Clinical Trials Kumar Jeetendra | October 13, 2022 VINS Bioproducts Limited, a leading immunological company, based in Hyderabad, in collaboration with the Centre for Cellular and Molecular Biology (CCMB) and the University of Hyderabad (UoH), announced the successful completion of Phase 2 Clinical Trials of VINCOV-19, India’s first antidote and a cure against SARS-CoV-2 virus. VINCOV-19 is now ready for market authorization and …
Cipla’s Indore plant joins the World Economic Forum’s (WEF) prestigious Lighthouse Network Kumar Jeetendra | October 11, 2022 Cipla Limited (BSE: 500087; NSE: CIPLA EQ) (“Cipla”) today announced that its Indore Oral Solid Dosage (OSD) plant has been designated by the World Economic Forum as an ‘Advanced Fourth Industrial Revolution (4IR) Lighthouse’. This is the first Cipla facility to receive the coveted recognition. The organisation is amongst the first pharmaceutical companies in India …
‘Listen to the Future’- Cipla’s digital film reinforces its ESG commitments Kumar Jeetendra | September 14, 2022 Mumbai, India, 14th September: Cipla Limited launched a thought-provoking brand film ‘Listen to the Future’ to reiterate the company’s ESG goals for 2030. To bring alive its ethos of contributing toward a greener environment and sustainable value creation, the film creatively highlights the importance of positive actions through the lens of children. The brand film …
Cipla Health’s “Naselin Shubhratri, Prajapati – The Guard” campaign bags “Silver” at Effie APAC Awards 2022 Kumar Jeetendra | September 9, 2022 Mumbai, 9 September: Naselin, one of the leading nasal decongestant brands by Cipla Health has swayed the stage away by winning the “Silver” at the Effie APAC Awards for its captivating yet appealing “Naselin Shubhratri, Prajapati – The Guard” campaign. Naselin becomes Cipla’s first ever brand to win a marketing award in the Asian Pacific region, which is one of the industry’s …
Cipla receives USFDA approval for generic version of Revlimid® (lenalidomide capsules) Kumar Jeetendra | September 7, 2022 Mumbai, India/ New Jersey, United States, September 7, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) (“Cipla”) announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsule 5 mg, 10 mg, 15 mg and 25 mg from the United States Food and Drug Administration (US FDA). Cipla’s Lenalidomide …
Alembic Pharmaceuticals receives USFDA Final Approval for Chlorthalidone Tablets USP, 25 mg and 50 mg. Kumar Jeetendra | August 29, 2022 29th August 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Chlorthalidone Tablets USP, 25 mg and 50 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Hygroton Tablets, …
Pfizer ranked as leading company in Asia for covid-19 response and patient-centric approach by Asian patient groups Kumar Jeetendra | August 26, 2022 SINGAPORE, 26 AUGUST 2022 — Pfizer had been ranked first in its Covid-19 response, patient centricity, patient safety and bringing innovative, high-quality products amongst pharma companies in Asia in the ‘Corporate Reputation of Pharma’ survey by patient groups across the APAC region. Overall, the company is ranked second for its corporate reputation across Asian countries. …
Aleor Dermaceuticals Limited receives USFDA Final Approval for Adapalene and Benzoyl Peroxide Topical Gel, 0.3%/2.5%. Kumar Jeetendra | August 8, 2022 Alembic Pharmaceuticals Limited (Alembic) today announced that its wholly owned subsidiary, Aleor Dermaceuticals Limited (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Adapalene and Benzoyl Peroxide Topical Gel, 0.3%/2.5%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) …